A Phase 2 interventional study of Esmolol in Heart Failure and Cardiogenic Shock, sponsored by Erasmus Medical Center. Recruiting at 1 site in Netherlands. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2024-07-26.
Sponsored by Erasmus Medical Center · Phase 2, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 313 studies in Heart Failure with a site in Netherlands — 57 open to participants now, 80 under way, 13 of them phase 3. Heart Failure · Netherlands.
Among the 313 studies in Heart Failure with a site in Netherlands, this one is the 214th largest by planned enrollment of the 234 interventional ones that give a count, is one of 20 that started in 2024, is one of 43 in phase 2, reaches primary completion later than 14 of the 79 other live ones, and was the 276th registered.
6,340 studies on the registry are indexed under Heart Failure; 1,397 are open to participants now.
Browse Heart Failure studies →57 of the 313 studies in Heart Failure with a site in Netherlands are open now. Recruiting first, the newest first:
AstraZeneca · Sites in Netherlands, United States, Argentina and 29 more countries
Ages 18+
Eli Lilly and Company · Sites in Netherlands, United States, Japan and 2 more countries
Ages 18–65
Jasper Brugts MD PhD · Sites in Netherlands
Ages 18+
BrioHealth BV · Sites in Netherlands
Ages 18+
University Medical Center Groningen · Sites in Netherlands
Ages 18+
A study can be open while its sites in Netherlands have not opened yet or have stopped. Only those recruiting at a site in Netherlands →
Of the 968 Heart Failure studies recruiting now, 691 (71%) set no upper age limit and 90 (9%) stop at 75 or younger; 64 take children under 18; 97 take healthy volunteers.
This study: 18 Years and older · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
313 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 1 9 · Phase 2 55 · Phase 3 68 · Phase 4 12
First in 1983; this study’s year is marked. 20 started in 2024.
By drug class, each counting the studies that test any of its medicines:
This study's planned enrollment of 20 is below the median of 76 across 4,053 interventional studies indexed under Heart Failure.
Median enrollment 284 across the 234 interventional studies, 236 across the 76 observational. Of the 200 that completed or were terminated, 84 (42%) have results posted.
This tab as a report to print or save as PDF → With an account.
179 of 313 have an industry lead sponsor. The 10 most frequent:
Erasmus Medical Center is the lead sponsor of 479 studies on the registry; 182 are open to participants now.
Erasmus Medical Center has 9 studies filed under Heart Failure — fewer than ten, so there is no comparison to draw.
15 of the studies in Heart Failure with a site in Netherlands that are under way reach primary completion within a year, 2 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT06307652Phase 3AstraZenecaStudy to Evaluate the Effect of Balcinrenone/Dapagliflozin in Patients With Heart Failure and Impaired Kidney Function | 2027-04-16 |
| NCT05374291Phase 3University Medical Center GroningenThe RENAL LIFECYCLE Trial: A RCT to Assess the Effect of Dapagliflozin on Renal and Cardiovascular Outcomes in Patients With Severe CKD | 2027-07 |
| NCT06137261Franciscus GasthuisScreening Adults With Obesity to Reduce Heart Failure Events | 2026-12-08 |
| NCT06735404Radboud University Medical CenterRAPIDE: The Feasibility of a Hybrid Care Model | 2027-03 |
| NCT06641362VDI TechnologiesUltra-High Frequency - Electrocardiogram (UHF-ECG) for the Diagnosis of Ventricular Electrical Dyssynchrony (VED) | 2027-03 |
Add all 15 to your calendar (.ics) → With an account.
Among the 313 studies in Heart Failure with a site in Netherlands, from their registry updates:
This tab as a report to print or save as PDF → With an account.
In this phase 2, single center, randomized clinical pilot trial, investigators will study the effect of a strategy involving a reduction of beta receptor (BR) stimulation (by decreasing dobutamine dosages) and subsequent BR inhibition (through ultra-short acting betablockers), versus a (routine) strategy with continued BR stimulation through dobutamine infusion, on heart rate in patients with cardiogenic shock due to left- or bi-ventricular failure being supported by V-A ECMO.
Despite the great benefits of Venoarterial ExtraCorporeal Membrane Oxygenation (V-A ECMO) and its rapidly increasing usage, even today, 30 till 70 percent of patients cannot be weaned from ECMO support and up to 50 percent of patients will eventually die in the first year. These high incidences of mortality and failure to wean from V-A ECMO support seem largely attributable to failure of the heart to recover in the context of inotropic drug administration and high sympathetic drive due to severe illness (further stressing an already failing heart). As V-A ECMO support creates a "safety window" where organ perfusion no longer relies on native cardiac output, therapeutic focus could be shifted to cardioprotective treatments. Cardioprotective treatments typically include beta blockers (BB) which have unequivocally shown benefits on mortality and morbidity in other patient categories with heart failure with reduced ejection fraction (HFrEF).
The investigators hypothesize that, in selected patients with cardiogenic shock undergoing V-A ECMO support, application of BBs is feasible and safe, and can effectively reduce heart rate.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Signs of insufficient trans cardiac flow:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
A reason a treatment, test or procedure should not be given to a particular person, such as an allergy, another illness or a medicine they take.
The study doctor’s estimate of how long someone is likely to live. Criteria use it so that people can stay in the study long enough for it to answer its question.
Contraindication
A reason a treatment, test or procedure should not be given to a particular person, such as an allergy, another illness or a medicine they take.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Life expectancy
The study doctor’s estimate of how long someone is likely to live. Criteria use it so that people can stay in the study long enough for it to answer its question.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
In the "beta receptor (BR) inhibition arm", patients are randomized to a biphasic strategy where BR stimulation is phased out and esmolol (BR blockade) is initiated in a sequential way. During a first phase, milrinone (a phosphodiesterase inhibitor which is routinely used in V-A ECMO supported patients) infusion will be initiated (if not already being given) at 0.25 mcg/kg/min and dobutamine dosages will be decreased every hour and eventually stopped according to the following sequence; 6 - 4 - 2 - 1 - 0 mcg/kg/min. In a second phase, esmolol is initiated with a dosage of 25 mcg/kg/min. The dose of the BB will be increased with increments of 25 mcg/kg/min every hour until reaching a heart rate between 50 and 70 bpm or a maximum dose of 200 mcg/kg/min. Prior to each dosage escalation, a reassessment of the hemodynamic situation will be done. The BR inhibition strategy will be continued until 48 hours after randomization or earlier when deemed necessary by the treating physician.
Drug: Esmolol
The dosage of dobutamine infusion is at the discretion of the treating physician but is typically continued until 48 hours after randomization. All other medication will be managed according to the needs of the patient at the discretion of the treating physician.
A vey cardioselective, short-acting betablocker, with an ultra-short half life time.
Change (delta) in heart rate 24 hours after randomization.
The average heart rate on basis of all observations during 5 minutes at both time points (t=0 and t=24h).
Time frame: 24 hours after randomization
Percentage of patients having received esmolol
Time frame: after 48 hours
Vasopressor score
using the calculation as described in literature, excluding inotropic medication
Time frame: at baseline, 24 and 48 hours
Occurrence of new onset ventricular and/or atrial arrhythmias after randomization
Time frame: during the first 48 hours
Left ventricular outflow tract velocity time integral (LVOT VTI)
Echocardiography parameters
Time frame: at baseline, 24 and 48 hours
Cardiac output
Pulmonary arterial catheter parameter
Time frame: at baseline, 24 and 48 hours
Stroke volume index
Pulmonary arterial catheter parameter
Time frame: at baseline, 24 and 48 hours
Pulmonary capillary wedge pressure
Pulmonary arterial catheter parameter
Time frame: at baseline, 24 and 48 hours
Central venous pressure
Pulmonary arterial catheter parameter
Time frame: at baseline, 24 and 48 hours
Mixed venous oxygen saturation (SvO2)
Pulmonary arterial catheter parameter
Time frame: at baseline, 24 and 48 hours
Lactate level
Time frame: at baseline, 24 and 48 hours
Troponin
measured at baseline, 24- and 48- hours after randomization, and Area Under the Curve (AUC)
Time frame: At 24 and 48 hours after randomization
Myocardial oxygen consumption
Estimated by calculating the pressure volume (PV) area on basis of non-invasive PV loop assessments using echocardiography and pulmonary artery catheter measurements
Time frame: At 24 and 48 hours after randomization
Plasma NT-proBNP levels
Biomarker for cardiac stretch
Time frame: At baseline and 48 hours after randomization
Plasma Creatine Kinase MB levels
Biomarker for cardiac injury
Time frame: At baseline and 48 hours after randomization
FiO2 suppletion
Time frame: At 24 and 48 hours after randomization
Plasma metanephrine levels
Time frame: At baseline and 24 after randomization
Plasma normetanephrines levels
Time frame: At baseline and 24 after randomization
Maximum median dosages of esmolol
Time frame: after 48 hours
Ejection fraction (EF)
Echocardiography parameters
Time frame: at baseline, 24 and 48 hours
Tricuspid annular plane systolic excursion (TAPSE).
Echocardiography parameters
Time frame: at baseline, 24 and 48 hours
Positive End Expiratory Pressure (PEEP) level
Time frame: At 24 and 48 hours after randomization
Started Jun 2024 (actual). Primary completion is estimated for Dec 2025, 18 months after the start.
Of 111 non-industry phase 2 interventional studies under Heart Failure, half reached primary completion within 39 months of starting (the median), counting those still running; a quarter within 21 and three quarters within 66. This study's planned 18 months is below that.
Counting every sponsor, half of 185 studies reached it within 29 months; a quarter within 17 and three quarters within 47.
How these figures are worked out, and which studies are left out of them.
Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.
Contact study teamGet an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drug tested here: Esmolol